Anders Lundstrom Acquires 575,000 Shares of Shield Therapeutics plc (LON:STX) Stock

Shield Therapeutics plc (LON:STX) insider Anders Lundstrom bought 575,000 shares of Shield Therapeutics stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of GBX 4 ($0.05) per share, for a total transaction of £23,000 ($28,949.02).

Shield Therapeutics Price Performance

Shares of LON STX opened at GBX 4.14 ($0.05) on Friday. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The company has a market cap of £40.83 million, a PE ratio of -1.07 and a beta of 1.42. The business has a 50-day simple moving average of GBX 2.81 and a two-hundred day simple moving average of GBX 3.40. Shield Therapeutics plc has a fifty-two week low of GBX 1.06 ($0.01) and a fifty-two week high of GBX 5.95 ($0.07).

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.